Nectar Lifesciences Limited (NSE:NECLIFE)
India · Delayed Price · Currency is INR 11.44
-0.19 (-1.63%)
Jun 19, 2026, 3:29 PM IST
Nectar Lifesciences Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1,786
Market Cap
2.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | - | - | - |
| Mar 31, 2025 | 16.70B | -142.05M | -0.84% |
| Mar 31, 2024 | 16.85B | 1.61B | 10.56% |
| Mar 31, 2023 | 15.24B | -1.45B | -8.70% |
| Mar 31, 2022 | 16.69B | 1.26B | 8.13% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sigachi Industries | 4.86B |
| Jagsonpal Pharmaceuticals | 2.87B |
| Balaxi Pharmaceuticals | 2.70B |
| Valiant Laboratories | 2.37B |
| Bafna Pharmaceuticals | 1.51B |
| Vaishali Pharma | 1.09B |
| Alpa Laboratories | 1.06B |
| Par Drugs and Chemicals | 1.04B |
Nectar Lifesciences News
- 1 year ago - Nectar Lifesciences shares fall 15% as it announces sale of core business division - Business Upturn
- 1 year ago - Nectar Lifesciences shares hit 5% lower circuit, down 10% in two days amid EU regulatory concerns - Business Upturn
- 1 year ago - Nectar Lifesciences shares surge nearly 5% as Q3 profit jumps 400% YoY - Business Upturn
- 1 year ago - Nectar Lifesciences Q3 FY25 results: Profit after tax rises nearly 400% YoY to Rs 7.84 crore - Business Upturn